Feb 10 (Reuters) - Immix Biopharma Inc IMMX.O:
IMMIX BIOPHARMA RECEIVES FDA REGENERATIVE MEDICINE ADVANCED THERAPY (RMAT) DESIGNATION FOR NXC-201, STERICALLY-OPTIMIZED CAR-T FOR RELAPSED/REFRACTORY AL AMYLOIDOSIS
IMMIX BIOPHARMA INC: ENROLLMENT IN NEXICART-2 STUDY ACCELERATING; NEXT UPDATE PLANNED FOR H1 2025
Source text: ID:nGNXbjs757
Further company coverage: IMMX.O